EHA 2024丨Bright Future Ahead: Key Developments in Luspatercept Treatment for Lower-Risk MDS Interpreted by Dr. Chungkang Chang

EHA 2024丨Bright Future Ahead: Key Developments in Luspatercept Treatment for Lower-Risk MDS Interpreted by Dr. Chungkang Chang

2024.08.28
The European Hematology Association (EHA) annual meeting, one of the most influential international academic conferences in the field of hematology, gathers numerous experts and scholars worldwide every year. The aim is to share and deeply discuss innovative ideas and the latest scientific and clinical research advancements in hematology, thereby promoting continuous progress in the field. This year’s conference unveiled the latest results from studies on the use of the erythroid maturation agent luspatercept in the treatment of lower-risk myelodysplastic syndromes (LR-MDS), demonstrating promising therapeutic potential. Oncology Frontier - Hematology Frontier invited Dr. Chungkang Chang , Director of the Hematology Department at Shanghai Sixth People’s Hospital Affiliated to Shanghai JiaoTong University and Deputy Director of the Shanghai Blood Research Institute, to provide an in-depth analysis of the field's current status and research content, aiming to offer valuable references for clinical practice.
Dr. Sujun Zheng: Advances in the Diagnosis and Treatment of Inactive HBsAg Carriers

Dr. Sujun Zheng: Advances in the Diagnosis and Treatment of Inactive HBsAg Carriers

2024.08.28
According to estimates from the Polaris Observatory, the prevalence of inactive hepatitis B surface antigen (HBsAg) carriers in the general population in China was 6.1% in 2016, with approximately 86 million people chronically infected with HBV. This suggests that around 36.08% of these individuals are inactive HBsAg carriers (IHC), equating to about 30.96 million people. The definitions and treatment recommendations for IHC vary across national or regional chronic hepatitis B (CHB) guidelines. As research into the natural history of CHB deepens and antiviral treatment strategies evolve, the management of HBV infection is gradually changing. At a recent Beijing Hepatology Academic Annual Meeting, Dr. Sujun Zheng from Beijing You An Hospital, Capital Medical University, presented an insightful report on "Advances in the Diagnosis and Treatment of Inactive HBsAg Carriers." Here, we summarize the key points.
SIFIC: Leading with Wisdom, Embracing Openness and Innovation

SIFIC: Leading with Wisdom, Embracing Openness and Innovation

2024.08.28
Recently, the 20th Shanghai International Forum for Infection Control (SIFIC) and the 8th Oriental Forum on Complex Infectious Diseases (OFCID), along with the Annual Academic Meeting of the Global Chinese Clinical Microbiology and Infectious Diseases Society, were successfully held in Shanghai. Infectious Diseases Frontier had the privilege of interviewing several administrators of the SIFIC forum at the event. They shared the development journey of SIFIC and their personal growth stories from different perspectives. Through these real experiences, we gained insight into how SIFIC, with an open attitude and innovative spirit, is leading the development of infection control in China, while also witnessing how each participant has achieved personal growth and value enhancement in this process.
Dr. Davide Rossi: The Role of Liquid Biopsy (ctDNA) in the Diagnosis and Treatment of Malignant Lymphoma

Dr. Davide Rossi: The Role of Liquid Biopsy (ctDNA) in the Diagnosis and Treatment of Malignant Lymphoma

2024.08.27
In the field of lymphoma diagnosis and treatment, traditional methods such as tissue biopsy, while valuable, are increasingly showing limitations due to their invasive nature, inconvenience in repeated sampling, and inability to fully reflect tumor heterogeneity. Liquid biopsy, as an emerging non-invasive testing technology, is demonstrating great potential in the diagnosis and treatment of lymphoma. At the recently held "The 8th Hematologic Oncology Academic Conference of the Chinese Society of Clinical Oncology (CSCO)", Dr. Davide Rossi from the Swiss Institute for Experimental Cancer Research in Bellinzona shared exciting insights on "The Role of Liquid Biopsy (ctDNA) in the Diagnosis and Treatment of Malignant Lymphomas". "Hematology Frontier" specially invited Dr. Davide Rossi for an interview at the venue to further delve into this topic.
Dr. Owen O’Connor: The Vessel of Hope for Peripheral T-Cell Lymphoma Braves the Storm and Forges Ahead Fearlessly | The 8th Hematologic Oncology

Dr. Owen O’Connor: The Vessel of Hope for Peripheral T-Cell Lymphoma Braves the Storm and Forges Ahead Fearlessly | The 8th Hematologic Oncology

2024.08.27
In order to further improve the diagnostic and treatment level of leukemia and lymphoma in China, "The 8th Hematologic Oncology Academic Conference of CSCO," co-hosted by the Chinese Society of Clinical Oncology (CSCO), the Leukemia Expert Committee of CSCO, and the Lymphoma Expert Committee, and co-organized by the Harbin Hematological Tumor Research Institute and Peking University Cancer Hospital, was grandly held in Harbin from July 26 to 28. The conference aims to build an important platform for in-depth learning and extensive exchange for many experts and scholars in the field of hematologic oncology. On the occasion of the conference, "Hematology Frontier" specially invited Dr. Owen O'Connor, Chairman of the American Lymphoma Alliance and the University of Virginia Cancer Center, to conduct in-depth academic discussions and share exciting insights around the cutting-edge progress of Peripheral T-Cell Lymphoma (PTCL).
EHA Global Perspectives | Dr. Edward Laane: Advancing Breakthroughs in MM Treatment and PRO Standardization

EHA Global Perspectives | Dr. Edward Laane: Advancing Breakthroughs in MM Treatment and PRO Standardization

2024.08.27
Multiple myeloma (MM) has long been a focus of hematology research due to its complex nature and the challenges it presents in treatment. As treatment methods continue to advance and new drugs emerge, patient survival rates and quality of life are receiving unprecedented attention. In this context, the accurate measurement of patient-reported outcomes (PROs) becomes increasingly important. It not only helps us gain a deeper understanding of patients’ real experiences but also provides guidance for developing more precise treatment strategies. At the 29th Annual Congress of the European Hematology Association (EHA 2024), held from June 13-16, Dr. Edward Laane from Tartu University in Estonia presented groundbreaking research that not only made significant strides in MM treatment but also offered new perspectives and methods for the standardization of PRO measurements. Hematology Frontier invited Dr. Edward Laane to share his team’s research findings and his special insights from the conference.
Dr. Dong Ji: Exploring Liver Fibrosis Reversal and Personalized Treatment

Dr. Dong Ji: Exploring Liver Fibrosis Reversal and Personalized Treatment

2024.08.26
The liver is a powerful organ with complex physiological structures and functions. Liver fibrosis is a dynamic pathological process associated with various chronic liver diseases, ultimately leading to cirrhosis. In cirrhosis, the liver not only becomes harder but also shrinks in size, with imaging showing changes in the liver's appearance accompanied by alterations in hepatic hemodynamics. Recently, at the 10th Beijing Hepatology Academic Annual Conference in 2024, Hepatology Digest invited Dr. Dong Ji from the Fifth Medical Center of the Chinese PLA General Hospital to discuss the latest insights and strategies on liver fibrosis reversal. The interview has been compiled into this article for readers to reference.
Dr. Hui Wang: PURPOSE 1 Study Reveals Outstanding Efficacy of Long-Acting Injectable Lenacapavir in Preventing HIV Infection in Women

Dr. Hui Wang: PURPOSE 1 Study Reveals Outstanding Efficacy of Long-Acting Injectable Lenacapavir in Preventing HIV Infection in Women

2024.08.26
On July 24th, during the highly anticipated Co-Chairs' Choice session at the 25th International AIDS Conference in Munich, Germany, the PURPOSE 1 study was unveiled, highlighting a significant breakthrough in HIV prevention. The study demonstrated the exceptional efficacy of the long-acting injectable drug Lenacapavir in preventing HIV infection among women. The study was simultaneously published online in The New England Journal of Medicine. Conducted in South Africa and Uganda, this double-blind, randomized controlled trial compared different prevention strategies and found that biannual injections of Lenacapavir effectively blocked HIV infection, resulting in zero cases of infection. The efficacy of Lenacapavir far surpassed that of daily oral F/TAF and F/TDF. The study not only confirmed Lenacapavir's high effectiveness but also revealed its potential to improve patient adherence, offering a new solution to one of the major challenges in HIV prevention. With the widespread application of Lenacapavir, global HIV prevention strategies may be poised for significant change. Infectious Diseases Frontier invited Dr. Hui Wang from the Second Affiliated Hospital of Southern University of Science and Technology (Shenzhen Third People's Hospital) to provide an in-depth commentary and analysis of this study.